| Similar Articles |
|---|
 |
The Motley Fool
April 27, 2005
Charly Travers |
Thanks for the Ride, Transkaryotic Selling was the right move, but it's hard to let go of stocks you like. Transkaryotic has certainly done very well for its shareholders.   |
The Motley Fool
July 5, 2005
Bill Mann |
This Merger Deserves Revisiting Transkaryotic agreed to $37 per share from Shire Pharmaceuticals -- but that was before the good news rolled in. These shares are worth 30% more today. The market knows it. |
The Motley Fool
February 24, 2005
Charly Travers |
Transkaryotic's Turnaround This biotech spotlights superb management creating shareholder value. |
The Motley Fool
July 25, 2005
Charly Travers |
Transkaryotic Therapies: What's It Worth? U.K.-based Shire Pharmaceuticals has offered to buy Transkaryotic Therapies for $37 a share. Will shareholders be shortchanged? |
The Motley Fool
January 26, 2005
John Bluis |
Genzyme Feels the Heat Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease. |
The Motley Fool
March 3, 2011
Ryan McBride |
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. |
Chemistry World
January 26, 2015
Phillip Broadwith |
Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
February 3, 2010
Brian Orelli |
Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease. |
The Motley Fool
October 30, 2006
Brian Lawler |
Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
Chemistry World
November 4, 2015
Phillip Broadwith |
Shire to buy cardiovascular specialist Dyax The deal gives Shire access to Dyax's portfolio of approved and developmental drugs for treating hereditary angioedema. |
The Motley Fool
July 26, 2005
Gardner & Mann |
For Shame, Warburg Pincus What transpired as a result of misplaced priorities among these board members who are partners at private equity firm Warburg Pincus is a deal that is substantially underpriced based on Transkaryotic's fundamentals. |
The Motley Fool
July 23, 2009
Brian Orelli |
This Too Shall Pass ... Like a Kidney Stone Demand outstrips supply? Boo-hoo. Lowered guidance because a company can't make enough to keep up with demand. Example: Genzyme |
The Motley Fool
May 1, 2006
Rich Duprey |
Searching for Profits in R&D: Part 1 Here's why treating R&D as an investment can lead you to some up-and-coming small caps worthy of your investment dollars. |
The Motley Fool
August 31, 2011
Brian Orelli |
Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease. |
The Motley Fool
November 11, 2004
Marko Djuranovic |
Take a Shot on CancerVax? The company still isn't profitable, but big gains may be on the horizon for this biotech. |
The Motley Fool
October 9, 2007
Brian Lawler |
Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
The Motley Fool
May 25, 2011
David Williamson |
Pay Attention to Shire The British ADHD medicine maker is busy making big moves. |
The Motley Fool
August 20, 2007
Brian Lawler |
Are These Perfect Pharma Acquisitions? Weighing recent drug-industry deals' odds of success: AstraZeneca and MedImmune... Shire and New River Pharmaceuticals... Gilead and Myogen... |
Pharmaceutical Executive
August 1, 2013
William Looney |
Succinctly Shire: An Interview with CEO Flemming Ornskov Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate. |
The Motley Fool
July 7, 2010
Brian Orelli |
That's Gotta Hurt: Recommending the Competition Supply constraints continue to plague Genzyme. |
Pharmaceutical Executive
June 1, 2012 |
Raising the Stakes in CNS As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory. |
The Motley Fool
March 4, 2005
Rich Duprey |
Home Run Stocks You Already Own Boost your returns without reinventing the wheel. A familiar name in which you've already invested can be the catalyst to charge your portfolio with market-beating returns. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Chemistry World
November 11, 2013
Phillip Broadwith |
Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke. |
Pharmaceutical Executive
October 1, 2005 |
Thought Leader: Room for Improvement An interview with Randal J. Kirk, founder of New River Pharmaceuticals, whose drug technology team has made it its goal to introduce safer, more efficacious and reliable models of existing franchise drugs. |
The Motley Fool
January 9, 2006
Jim Gillies |
Be Not Afraid Don't let fear keep you from market-beating returns. Fear of losses. Fear of admitting a mistake. Fear of being left behind. Fear of buying a "loser." All of these fears can hobble an investor. Face your fears -- and beat the market. |
Chemistry World
April 14, 2008
Ananyo Bhattacharya |
Psychiatric Drug Ads 'Frequently Misleading' Advertisements for psychiatric drugs - including many top-selling antidepressants - often make claims that are either misleading or impossible to verify, according to a new US study. |
The Motley Fool
August 9, 2005
Seth Jayson |
The Investor's Frame of Mind Curiosity is the successful investor's prime attribute. |
Pharmaceutical Executive
October 1, 2011
William Looney |
Bravura Performer As chief executive of a trim, mid-size pharma player with a distinctive portfolio franchise, Angus Russell has made his reputation as an iconoclast -- the antagonist of bloat. |
